Terray’s AI Model Accelerates Drug Potency Prediction, Pose Not Needed

Terray’s AI Model Accelerates Drug Potency Prediction, Pose Not Needed

Jacob Berlin, PhD, CEO of Terray Therapeutics, explains that the critical element to “get right” for a preclinical drug discovery campaign is identifying molecules that rank best among the candidate set.   The AI drug discovery company is building an end-to-end pipeline to bring novel small molecule drugs from unseen chemical space to the clinic. Designing these therapeutics from scratch, without patent information or public datasets, will requi…

Terray says its AI model beats a popular open-source model at predicting how molecules bind with proteins

While most of AI drug discovery has followed AlphaFold with diffusion models, Terray Therapeutics says it has found success with a contrarian approach. In a recently posted preprint and blog post ...